High molecular weight adiponectin inhibits vascular calcification in renal allograft recipients.

Adiponectin (ADPN) prevents the development/recurrence of cardiovascular events via its anti-atherogenic effects. However, few long-term studies have examined the changes in serum ADPN levels and arterial calcification seen in renal allograft recipients.The effects of the serum ADPN level on arteria...

Full description

Bibliographic Details
Main Authors: Kanae Nomura-Nakayama, Hiroki Adachi, Nobuhiko Miyatake, Norifumi Hayashi, Keiji Fujimoto, Hideki Yamaya, Hitoshi Yokoyama
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5931493?pdf=render
id doaj-db0f47e470474ec18a6a9213996cec5a
record_format Article
spelling doaj-db0f47e470474ec18a6a9213996cec5a2020-11-25T02:19:48ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01135e019506610.1371/journal.pone.0195066High molecular weight adiponectin inhibits vascular calcification in renal allograft recipients.Kanae Nomura-NakayamaHiroki AdachiNobuhiko MiyatakeNorifumi HayashiKeiji FujimotoHideki YamayaHitoshi YokoyamaAdiponectin (ADPN) prevents the development/recurrence of cardiovascular events via its anti-atherogenic effects. However, few long-term studies have examined the changes in serum ADPN levels and arterial calcification seen in renal allograft recipients.The effects of the serum ADPN level on arterial calcification were examined in 51 Japanese renal allograft recipients. Abdominal aorta calcification was evaluated on computed tomography using the aortic calcification area index (ACAI). The change in the ACAI and serum high-molecular-weight (HMW)-ADPN fractions were studied over an 8-year period. The arterial expression of ADPN, ADPN receptors (AdipoR)1 and 2, and T-cadherin (cadherin-13) were also examined by immunohistochemistry.The change in the ACAI were grouped into quartiles and compared with the alterations in the serum levels of each ADPN fraction over an 8-year period. The change in the ACAI was much lower in the patients with highly elevated HMW-ADPN levels.Multiple regression analysis demonstrated that an advanced age at transplant and a history of cardiovascular complications were associated with an increased change in the ACAI, while higher HMW-ADPN concentrations were associated with improvements in the ACAI. Serum HDL-C level was also identified as a positive factor to increase serum HMW-ADPN level.In immunohistochemical examinations, ADPN was detected on CD31-positive arterial endothelial cells from renal allograft biopsy samples. ADPN co-localized with T-cadherin and AdipoR1, but only partially co-localized with AdipoR2.Both HMW-ADPN and HDL-C might inhibit the progression of vascular calcification by promoting ADPN binding to vascular endothelial cells via T-cadherin and AdipoR in Japanese renal allograft recipients.http://europepmc.org/articles/PMC5931493?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Kanae Nomura-Nakayama
Hiroki Adachi
Nobuhiko Miyatake
Norifumi Hayashi
Keiji Fujimoto
Hideki Yamaya
Hitoshi Yokoyama
spellingShingle Kanae Nomura-Nakayama
Hiroki Adachi
Nobuhiko Miyatake
Norifumi Hayashi
Keiji Fujimoto
Hideki Yamaya
Hitoshi Yokoyama
High molecular weight adiponectin inhibits vascular calcification in renal allograft recipients.
PLoS ONE
author_facet Kanae Nomura-Nakayama
Hiroki Adachi
Nobuhiko Miyatake
Norifumi Hayashi
Keiji Fujimoto
Hideki Yamaya
Hitoshi Yokoyama
author_sort Kanae Nomura-Nakayama
title High molecular weight adiponectin inhibits vascular calcification in renal allograft recipients.
title_short High molecular weight adiponectin inhibits vascular calcification in renal allograft recipients.
title_full High molecular weight adiponectin inhibits vascular calcification in renal allograft recipients.
title_fullStr High molecular weight adiponectin inhibits vascular calcification in renal allograft recipients.
title_full_unstemmed High molecular weight adiponectin inhibits vascular calcification in renal allograft recipients.
title_sort high molecular weight adiponectin inhibits vascular calcification in renal allograft recipients.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2018-01-01
description Adiponectin (ADPN) prevents the development/recurrence of cardiovascular events via its anti-atherogenic effects. However, few long-term studies have examined the changes in serum ADPN levels and arterial calcification seen in renal allograft recipients.The effects of the serum ADPN level on arterial calcification were examined in 51 Japanese renal allograft recipients. Abdominal aorta calcification was evaluated on computed tomography using the aortic calcification area index (ACAI). The change in the ACAI and serum high-molecular-weight (HMW)-ADPN fractions were studied over an 8-year period. The arterial expression of ADPN, ADPN receptors (AdipoR)1 and 2, and T-cadherin (cadherin-13) were also examined by immunohistochemistry.The change in the ACAI were grouped into quartiles and compared with the alterations in the serum levels of each ADPN fraction over an 8-year period. The change in the ACAI was much lower in the patients with highly elevated HMW-ADPN levels.Multiple regression analysis demonstrated that an advanced age at transplant and a history of cardiovascular complications were associated with an increased change in the ACAI, while higher HMW-ADPN concentrations were associated with improvements in the ACAI. Serum HDL-C level was also identified as a positive factor to increase serum HMW-ADPN level.In immunohistochemical examinations, ADPN was detected on CD31-positive arterial endothelial cells from renal allograft biopsy samples. ADPN co-localized with T-cadherin and AdipoR1, but only partially co-localized with AdipoR2.Both HMW-ADPN and HDL-C might inhibit the progression of vascular calcification by promoting ADPN binding to vascular endothelial cells via T-cadherin and AdipoR in Japanese renal allograft recipients.
url http://europepmc.org/articles/PMC5931493?pdf=render
work_keys_str_mv AT kanaenomuranakayama highmolecularweightadiponectininhibitsvascularcalcificationinrenalallograftrecipients
AT hirokiadachi highmolecularweightadiponectininhibitsvascularcalcificationinrenalallograftrecipients
AT nobuhikomiyatake highmolecularweightadiponectininhibitsvascularcalcificationinrenalallograftrecipients
AT norifumihayashi highmolecularweightadiponectininhibitsvascularcalcificationinrenalallograftrecipients
AT keijifujimoto highmolecularweightadiponectininhibitsvascularcalcificationinrenalallograftrecipients
AT hidekiyamaya highmolecularweightadiponectininhibitsvascularcalcificationinrenalallograftrecipients
AT hitoshiyokoyama highmolecularweightadiponectininhibitsvascularcalcificationinrenalallograftrecipients
_version_ 1724874256799498240